Artivion (NYSE:AORT) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Artivion to “sell” from “hold,” although the broader analyst consensus remains “Moderate Buy,” with seven Buy ratings and one Sell rating and an average price target of $44.67.
• Artivion reported quarterly EPS of $0.13 and revenue of $125.76 million, exceeding the $119.99 million consensus revenue estimate. Analysts expect full-year EPS of approximately $0.45.
• The stock opened at $29.22, versus a 12-month range of $19.16 to $48.25; institutional investors own 86.37% of the company, while recent insider transactions included share sales by two senior vice presidents.

Artivion (NYSE:AORT - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday, June 1st. Weiss Ratings downgraded Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday. Citigroup reiterated a "market outperform" rating on shares of Artivion in a research note on Tuesday, July 21st. Needham & Company LLC restated a "buy" rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Finally, Citizens Jmp reduced their price objective on shares of Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.67.

Artivion Price Performance

Shares of NYSE:AORT opened at $29.22 on Friday. The company's fifty day moving average is $24.28 and its two-hundred day moving average is $30.59. The company has a market cap of $1.42 billion, a P/E ratio of -417.33 and a beta of 1.25. Artivion has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Equities analysts expect that Artivion will post 0.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 977 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares of the company's stock, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company's stock, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.30% of the company's stock.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Artivion in the 2nd quarter valued at $149,965,000. Vanguard Group Inc. increased its holdings in shares of Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company's stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. Morgan Stanley raised its position in shares of Artivion by 0.8% during the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company's stock valued at $102,930,000 after buying an additional 18,248 shares during the last quarter. State Street Corp lifted its stake in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company's stock valued at $72,288,000 after buying an additional 44,641 shares during the period. Finally, Fred Alger Management LLC grew its position in Artivion by 4.2% during the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company's stock worth $62,603,000 after buying an additional 55,322 shares in the last quarter. Institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source